Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
Clinical trial NCT03769103 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03769103
- Sponsor
- British Columbia Cancer Agency
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-19
- Primary completion
- 2025-04-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.